Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial
National Natural Science Foundation of China, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Medical Discipline Construction Project, and Tianjin Key Medical Discipline (Specialty) Construction Project.
Authors
- Zewei Li (ORCID: https://orcid.org/0000-0001-6654-2003)
- Cihui Yan (ORCID: https://orcid.org/0000-0002-9391-0403)
- Na Bai (ORCID: https://orcid.org/0000-0002-9523-1279)
- Fuliang Cao (ORCID: https://orcid.org/0000-0003-2332-3243)
- Yufei Wang (ORCID: https://orcid.org/0009-0002-5685-6580)
- Shu-Heng Jiang
- Zhunhao Zheng
- Linrui Gao
- Ping Wang
- Wencheng Zhang
- Tian Zhang
- Xi Chen
- Jiacheng Li
- Gang Zhao
- Jie Dong
- Qingsong Pang
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1016/j.eclinm.2026.103758
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00